1. Home
  2. RAPP vs CRVS Comparison

RAPP vs CRVS Comparison

Compare RAPP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$36.77

Market Cap

1.3B

Sector

N/A

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$14.71

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAPP
CRVS
Founded
2022
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2024
2016

Fundamental Metrics

Financial Performance
Metric
RAPP
CRVS
Price
$36.77
$14.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$48.50
$28.20
AVG Volume (30 Days)
251.7K
1.0M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
24.34
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$3.15
52 Week High
$42.27
$26.95

Technical Indicators

Market Signals
Indicator
RAPP
CRVS
Relative Strength Index (RSI) 74.26 47.15
Support Level $25.48 $12.95
Resistance Level $42.27 $18.73
Average True Range (ATR) 1.93 0.87
MACD 0.60 0.19
Stochastic Oscillator 97.79 54.19

Price Performance

Historical Comparison
RAPP
CRVS

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: